タカダ　タクマ   TAKADA Takuma   髙田　卓磨    所属   研究施設 研究施設    職種   助教
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study.
掲載誌名	正式名：Thrombosis research 略　 称：Thromb Res ISSNコード：18792472/00493848
掲載区分	国外
巻・号・頁	235,pp.107-115
著者・共著者	Sueta Daisuke, Yamashita Yugo, Morimoto Takeshi, Muraoka Nao, Umetsu Michihisa, Nishimoto Yuji, Takada Takuma, Ogihara Yoshito, Nishikawa Tatsuya, Ikeda Nobutaka, Otsui Kazunori, Tsubata Yukari, Shoji Masaaki, Shikama Ayumi, Hosoi Yutaka, Tanabe Yasuhiro, Chatani Ryuki, Tsukahara Kengo, Nakanishi Naohiko, Kim Kitae, Ikeda Satoshi, Mo Makoto, Kimura Takeshi, Tsujita Kenichi,
発行年月	2024/03
概要	BACKGROUND:The multicenter, open-label, randomized clinical trial ONCO DVT compared 3-month and 12-month edoxaban treatment regimens for isolated distal deep vein thrombosis (DVT) and suggested potential benefits of prolonged edoxaban treatment in terms of thrombotic risk. However, the risk-benefit balance of prolonged edoxaban treatment in patients with renal function remains unclear.OBJECTIVES:To compare the safety and efficacy of 3-month and 12-month edoxaban treatment regimens in patients with cancer-associated isolated distal DVT and different renal functions.METHODS:This pre-specified subgroup analysis of the ONCO DVT study included 601 patients divided into subgroups according to renal function using a 50 mL/min creatinine clearance (Ccr) cutoff. The primary endpoint was symptomatic recurrent venous thromboembolism (VTE) and VTE-related death at 12 months and the major secondary endpoint was major bleeding at 12 months.RESULTS:Among the 601 patients, 131 (21.8 %) comprised the renal dysfunction subgroup. The primary endpoint occurred in 6 (9.7 %) and 1 (1.4 %) patients in the 3-month and 12-month edoxaban groups in the renal dysfunction subgroup, respectively, and in 16 (6.6 %) and 2 (0.9 %) patients in the no renal dysfunction subgroup, respectively. The major secondary endpoint occurred in 9 (14.5 %) and 7 (10.1 %) patients in the 12-month and 3-month edoxaban groups in the renal dysfunction subgroup, and in 13 (5.3 %) and 21 (9.3 %) patients in the no renal dysfunction subgroup, respectively.CONCLUSIONS:A 12-month edoxaban regiment was superior to a 3-month treatment in terms of thrombotic risk irrespective of renal function. A higher bleeding risk was not identified in patients with renal dysfunction who received prolonged edoxaban treatment.
DOI	10.1016/j.thromres.2024.01.021
PMID	38335565